Search research articles
Contact Us
Filters
Showing results (11-20 of 85) with videos related to
Page
of 9
Sort By:
Translational Andrology and Urology
|
April 14, 2021
Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States
Matteo Santoni, Alessia Cimadamore, Francesco Massari, et al.
Clinical Drug Investigation
|
January 30, 2020
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients
Vincenzo Di Nunno, Matteo Santoni, Veronica Mollica, et al.
Current Oncology (Toronto, Ont.)
|
July 26, 2024
Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant Setting
Halima Abahssain, Amine Souadka, Rania Alem, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
January 14, 2022
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study
Alessandro Rizzo, Matteo Santoni, Veronica Mollica, et al.
Expert Review of Anticancer Therapy
|
May 15, 2023
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer
Giacomo Nuvola, Matteo Santoni, Mimma Rizzo, et al.
Immunotherapy
|
November 27, 2018
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis
Matteo Santoni, Alessandro Conti, Sebastiano Buti, et al.
Cancers
|
October 23, 2021
Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views
Gaetano Aurilio, Matteo Santoni, Francesco Massari, et al.
BMC Cancer
|
November 20, 2020
Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER<sup>+</sup>HER2<sup>-</sup>Rb wild-type and knock-down in breast cancer cell lines
Oliviero Marinelli, Emanuela Romagnoli, Federica Maggi, et al.
Expert Opinion on Investigational Drugs
|
February 18, 2021
An update on investigational therapies that target STAT3 for the treatment of cancer
Matteo Santoni, Francesca Miccini, Alessia Cimadamore, et al.
Future Oncology (London, England)
|
June 5, 2019
BAP1 in solid tumors
Vincenzo Di Nunno, Giorgio Frega, Matteo Santoni, et al.
Page
of 9
Search research articles
Search
Showing results (11-20 of 85) with videos related to
Sort By:
Page
of 9
Translational Andrology and Urology
|
April 14, 2021
Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States
Matteo Santoni, Alessia Cimadamore, Francesco Massari, et al.
Clinical Drug Investigation
|
January 30, 2020
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients
Vincenzo Di Nunno, Matteo Santoni, Veronica Mollica, et al.
Current Oncology (Toronto, Ont.)
|
July 26, 2024
Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant Setting
Halima Abahssain, Amine Souadka, Rania Alem, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
January 14, 2022
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study
Alessandro Rizzo, Matteo Santoni, Veronica Mollica, et al.
Expert Review of Anticancer Therapy
|
May 15, 2023
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer
Giacomo Nuvola, Matteo Santoni, Mimma Rizzo, et al.
Immunotherapy
|
November 27, 2018
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis
Matteo Santoni, Alessandro Conti, Sebastiano Buti, et al.
Cancers
|
October 23, 2021
Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views
Gaetano Aurilio, Matteo Santoni, Francesco Massari, et al.
BMC Cancer
|
November 20, 2020
Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER<sup>+</sup>HER2<sup>-</sup>Rb wild-type and knock-down in breast cancer cell lines
Oliviero Marinelli, Emanuela Romagnoli, Federica Maggi, et al.
Expert Opinion on Investigational Drugs
|
February 18, 2021
An update on investigational therapies that target STAT3 for the treatment of cancer
Matteo Santoni, Francesca Miccini, Alessia Cimadamore, et al.
Future Oncology (London, England)
|
June 5, 2019
BAP1 in solid tumors
Vincenzo Di Nunno, Giorgio Frega, Matteo Santoni, et al.
Page
of 9